Pathways for Dolutegravir Transformation from a Daily Oral to a Once-a-Year Parenteral Medicine

An “ultra” long-acting (LA) integrase strand transfer inhibitor was created by screening a library of monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led, to the best of our knowledge, a “first in class” 18-carbon chain modified prodrug nanocrystal (coined as NM2DTG). Ideal physiochemical and pharmacokinetic (PK) properties facilitated slow drug release from tissue macrophage prodrug depot stores for up to one year after a single intramuscular injection. Both the muscle injection site and secondary lymphoid tissues were depots of prodrug hydrolysis; dependent on nanocrystal dissolution and prodrug release rates, drug-depot volume, perfusion, and cell-tissue pH. Each affected an extended NM2DTG apparent half-life by recorded PK parameters. The NM2DTG LA product can impact therapeutic adherence, tolerability, and access to a widely used integrase inhibitor in resource-limited and rich settings to reduce HIV-1 transmission and achieve optimal treatment outcomes.

[1]  H. Gendelman,et al.  Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles , 2021, Nature Communications.

[2]  M. Khan,et al.  Ultra-long Acting Prodrug of Dolutegravir and Delivery System - Physicochemical, Pharmacokinetic and Formulation Characterizations. , 2021, International journal of pharmaceutics.

[3]  S. Montgomery,et al.  Biodegradable Polymeric Solid Implants for Ultra-Long-Acting Delivery of Single or Multiple Antiretroviral Drugs. , 2021, International journal of pharmaceutics.

[4]  H. Gendelman,et al.  Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir , 2021, Nature Communications.

[5]  J. Garcia,et al.  A new engineering process of biodegradable polymeric solid implants for ultra-long-acting drug delivery , 2020, International journal of pharmaceutics: X.

[6]  Rachna Gupta,et al.  Emerging Trends in the Long-acting Antiretroviral Therapy: Current Status and Therapeutic Challenges. , 2020, Current HIV research.

[7]  S. Swindells,et al.  Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials , 2020, Journal of acquired immune deficiency syndromes.

[8]  Jennifer Abbasí.  Promising Early Results for Potent, Long-Acting HIV Injection. , 2020, Journal of the American Medical Association (JAMA).

[9]  V. Soriano,et al.  Long-acting antiretroviral therapy , 2020, Nature Materials.

[10]  K. Scarsi.  Chasing the cabotegravir tail: implications for prevention. , 2020, The lancet. HIV.

[11]  M. Horberg,et al.  Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016 , 2020, JAMA network open.

[12]  M. Proschan,et al.  Kinetics of plasma HIV rebound in the era of modern antiretroviral therapy. , 2020, The Journal of infectious diseases.

[13]  J. Meza,et al.  A Year-Long Extended Release Nanoformulated Cabotegravir Prodrug , 2020, Nature Materials.

[14]  O. Baser,et al.  Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries , 2020, AIDS Research and Therapy.

[15]  M. Yuen,et al.  Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed , 2020, JHEP reports : innovation in hepatology.

[16]  J. Currier.  Monthly Injectable Antiretroviral Therapy - Version 1.0 of a New Treatment Approach. , 2020, New England Journal of Medicine.

[17]  Yucai Wang,et al.  Protein Binding Affinity of Polymeric Nanoparticles as a Direct Indicator of Their Pharmacokinetics. , 2020, ACS nano.

[18]  H. Gendelman,et al.  Creation of a long-acting rilpivirine prodrug nanoformulation. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[19]  H. Gendelman,et al.  Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice , 2019, Nature Communications.

[20]  C. V. van Halsema,et al.  Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential , 2019, HIV/AIDS.

[21]  H. Patel,et al.  Rats and rabbits as pharmacokinetic screening tools for long acting intramuscular depots: case study with paliperidone palmitate suspension , 2019, Xenobiotica; the fate of foreign compounds in biological systems.

[22]  H. Gendelman,et al.  HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication , 2019, Journal of Neuroimmune Pharmacology.

[23]  R. Mumper,et al.  Ultra-long-acting removable drug delivery system for HIV treatment and prevention , 2018, Nature Communications.

[24]  H. Gendelman,et al.  Creation of a long-acting nanoformulated dolutegravir , 2018, Nature Communications.

[25]  H. Gendelman,et al.  Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques , 2017, Antimicrobial Agents and Chemotherapy.

[26]  R. Linkins,et al.  Measles and rubella elimination: learning from polio eradication and moving forward with a diagonal approach , 2017, Expert review of vaccines.

[27]  H. Gendelman,et al.  Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles , 2017, Biomaterials.

[28]  D. Podzamczer,et al.  Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial , 2017, The Lancet.

[29]  H. Gendelman,et al.  Long-acting slow effective release antiretroviral therapy , 2017, Expert opinion on drug delivery.

[30]  Kun Chen,et al.  Barriers to HIV Medication Adherence as a Function of Regimen Simplification , 2017, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[31]  D. Ho,et al.  Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251 , 2017, AIDS.

[32]  M. Gill,et al.  Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients , 2016, PloS one.

[33]  P. Annaert,et al.  Modeling the Time Course of the Tissue Responses to Intramuscular Long-acting Paliperidone Palmitate Nano-/Microcrystals and Polystyrene Microspheres in the Rat , 2016, Toxicologic pathology.

[34]  W. Heneine,et al.  Cabotegravir long-acting for HIV-1 prevention , 2015, Current opinion in HIV and AIDS.

[35]  D. Havlir,et al.  Implementation challenges for long-acting antivirals as treatment , 2015, Current opinion in HIV and AIDS.

[36]  V. Herring,et al.  The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance? , 2013, Pharmacotherapy.

[37]  J. Montaner,et al.  Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource‐limited settings , 2011, HIV medicine.

[38]  J. Bartlett,et al.  Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. , 2009, The Lancet. Infectious diseases.

[39]  L. Mofenson,et al.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[40]  R. Jain,et al.  Limitations of current antiretroviral agents and opportunities for development. , 2006, Current pharmaceutical design.

[41]  J. Montaner,et al.  Adverse effects of antiretroviral therapy for HIV infection. , 2004, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[42]  Dawn G Goodman,et al.  Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.

[43]  M. Hashida,et al.  Pharmacokinetic Analysis of Drug Absorption from Muscle Based on a Physiological Diffusion Model: Effect of Molecular Size on Absorption , 1992, Pharmaceutical Research.

[44]  R. Landovitz,et al.  Long-acting injectable cabotegravir for the prevention of HIV infection. , 2020, Current opinion in HIV and AIDS.

[45]  K. Zoon,et al.  Control of Viral Infections and Diseases , 1996 .

[46]  F. Fenner.  Smallpox and its eradication , 1988 .